In This Article:
-
The U.S. Centers for Disease Control and Prevention's (CDC) advisory committee recommended using Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine as a two-dose primary series for individuals aged 18 and above.
-
The committee will submit its recommendation to the Director of the CDC for review and endorsement.
-
CDC director Rochelle Walensky said the decision "expanded the options available" to U.S. adults for vaccinations.
-
"If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated," she said.
-
Related: Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
-
The U.S. government has secured 3.2 million Novavax vaccine doses.
-
Reuters reported that Novavax hopes its protein-based shot can reach wider acceptance among vaccine skeptics because it uses an older technology than the messenger RNA vaccines.
-
Protein-based vaccines have been used for decades to combat hepatitis B and influenza.
-
In a 30,000-participant clinical trial, the vaccine was around 90% effective at preventing illness from COVID.
-
Price Action: NVAX shares are up 0.88% at $58.51 during the premarket session on the last check Wednesday.
-
Photo by hakan german from Pixabay
See more from Benzinga
-
WHO, UNICEF Sound Alarm As Pandemic Leads Largest Fall In Kids Vaccinations In 30 Years
-
Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.